AbbVie Inc. (ABBV)

Basic

  • Market Cap

    $316.04B

  • EV

    $363.84B

  • Shares Out

    1,766.47M

  • Revenue

    $54.32B

  • Employees

    50,000

Margins

  • Gross

    69.21%

  • EBITDA

    48.53%

  • Operating

    32.51%

  • Pre-Tax

    11.51%

  • Net

    8.95%

  • FCF

    40.62%

Returns (5Yr Avg)

  • ROA

    9.22%

  • ROTA

    -17.35%

  • ROE

    56.19%

  • ROCE

    18.91%

  • ROIC

    17.22%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $180.74

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $12.82B

  • Net Debt

    $47.76B

  • Debt/Equity

    5.83

  • EBIT/Interest

    7.94

Growth (CAGR)

  • Rev 3Yr

    5.85%

  • Rev 5Yr

    10.65%

  • Rev 10Yr

    11.2%

  • Dil EPS 3Yr

  • Dil EPS 5Yr

    -5.76%

  • Dil EPS 10Yr

    0.61%

  • Rev Fwd 2Yr

    2.9%

  • EBITDA Fwd 2Yr

    5.48%

  • EPS Fwd 2Yr

    4.69%

  • EPS LT Growth Est

    7.45%

Dividends

  • Yield

  • Payout

    219.72%

  • DPS

    $5.99

  • DPS Growth 3Yr

    7.36%

  • DPS Growth 5Yr

    8.68%

  • DPS Growth 10Yr

    14.11%

  • DPS Growth Fwd 2Yr

    3.72%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Total Revenues

33,266

45,804

56,197

58,054

54,318

Total Revenues % Chg.

1.6%

37.7%

22.7%

3.3%

-6.4%

Cost of Goods Sold, Total

7,439

15,257

17,314

16,527

16,726

Gross Profit

25,827

30,547

38,883

41,527

37,592

Selling General & Admin Expenses, Total

6,763

9,867

11,872

12,084

12,904

R&D Expenses

5,377

6,003

6,820

6,487

7,038

Other Operating Expenses

-560

432

-1

-10

Other Operating Expenses, Total

11,580

15,870

19,124

18,570

19,932

Operating Income

14,247

14,677

19,759

22,957

17,660

Interest Expense, Total

-1,784

-2,454

-2,423

-2,230

-2,224

Interest And Investment Income

275

174

39

186

540

Net Interest Expenses

-1,509

-2,280

-2,384

-2,044

-1,684

Currency Exchange Gains (Loss)

-42

-71

-51

-148

-146

Other Non Operating Income (Expenses)

9

113

55

142

190

EBT, Excl. Unusual Items

12,705

12,439

17,379

20,907

16,020

Restructuring Charges

Merger & Related Restructuring Charges

-103

-1,912

-587

-768

-119

Gain (Loss) On Sale Of Investments

Gain (Loss) On Sale Of Assets

330

172

Asset Writedown

-1,030

-876

-4,230

In Process R&D Expenses

-385

-1,376

-1,124

-697

-778

Legal Settlements

-2,500

485

Other Unusual Items

-3,091

-5,753

-2,679

-2,761

-5,128

EBT, Incl. Unusual Items

8,426

3,398

12,989

13,477

6,250

Income Tax Expense

544

-1,224

1,440

1,632

1,377

Earnings From Continuing Operations

7,882

4,622

11,549

11,845

4,873

Minority Interest

-6

-7

-9

-10

Net Income

7,882

4,616

11,542

11,836

4,863

Preferred Dividend and Other Adjustments

40

60

74

54

43

Net Income to Common Incl Extra Items

7,842

4,556

11,468

11,782

4,820

Net Income to Common Excl. Extra Items

7,842

4,556

11,468

11,782

4,820

Total Shares Outstanding

1,478.9

1,765.1

1,768.3

1,769.2

1,765.9

Weighted Avg. Shares Outstanding

1,481

1,667

1,770

1,771

1,768

Weighted Avg. Shares Outstanding Dil

1,484

1,673

1,777

1,778

1,773

EPS

5.3

2.7

6.5

6.7

2.7

EPS Diluted

5.3

2.7

6.5

6.6

2.7

EBITDA

16,264

21,148

28,280

31,424

26,358